A
Alexey V. Danilov
Researcher at City of Hope National Medical Center
Publications - 183
Citations - 3313
Alexey V. Danilov is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Medicine. The author has an hindex of 25, co-authored 130 publications receiving 2039 citations. Previous affiliations of Alexey V. Danilov include Dartmouth–Hitchcock Medical Center & Memorial Hospital of Rhode Island.
Papers
More filters
Journal ArticleDOI
Functional genomic landscape of acute myeloid leukaemia
Jeffrey W. Tyner,Cristina E. Tognon,Cristina E. Tognon,Daniel Bottomly,Beth Wilmot,Stephen E. Kurtz,Samantha L. Savage,Nicola Long,Anna Reister Schultz,Elie Traer,Melissa L. Abel,Anupriya Agarwal,Aurora Blucher,Uma Borate,Jade Bryant,Russell T. Burke,Amy S. Carlos,Richie Carpenter,Joseph Carroll,Bill H. Chang,Cody Coblentz,Amanda d’Almeida,Rachel J. Cook,Alexey V. Danilov,Kim Hien T. Dao,Michie Degnin,Deirdre Devine,James Dibb,David K. Edwards,Christopher A. Eide,Christopher A. Eide,Isabel English,Jason M. Glover,Rachel Henson,Hibery Ho,Abdusebur Jemal,Kara Johnson,Ryan C. Johnson,Brian Junio,Andy Kaempf,Jessica Leonard,Chenwei Lin,Selina Qiuying Liu,Pierrette Lo,Marc M. Loriaux,Samuel B. Luty,Tara A. Macey,Jason D. MacManiman,Jacqueline Martinez,Motomi Mori,Dylan Nelson,Ceilidh Nichols,Jill Peters,Justin Ramsdill,Angela Rofelty,Robert Schuff,Robert P. Searles,Erik Segerdell,Rebecca Smith,Stephen E. Spurgeon,Tyler Sweeney,Aashis Thapa,Corinne Visser,Jake Wagner,Kevin Watanabe-Smith,Kristen Werth,Joelle Wolf,Libbey White,Amy Yates,Haijiao Zhang,Christopher R. Cogle,Robert H. Collins,Denise C. Connolly,Michael W. Deininger,Leylah Drusbosky,Christopher S. Hourigan,Craig T. Jordan,Patricia Kropf,Tara L. Lin,Micaela E. Martinez,Bruno C. Medeiros,Rachel R. Pallapati,Daniel A. Pollyea,Ronan T. Swords,Justin M. Watts,Scott Weir,David L. Wiest,Ryan M. Winters,Shannon K. McWeeney,Brian J. Druker,Brian J. Druker +90 more
TL;DR: Analyses of samples from patients with acute myeloid leukaemia reveal that drug response is associated with mutational status and gene expression; the generated dataset provides a basis for future clinical and functional studies of this disease.
Journal ArticleDOI
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies
Joseph J. Shatzel,Sven R. Olson,Derrick Tao,Owen J. T. McCarty,Alexey V. Danilov,Thomas G. DeLoughery +5 more
TL;DR: The pathophysiology of ibrutinib‐mediated bleeding is described, risk reduction strategies for common clinical scenarios associated with ibrUTinib are suggested, and patients are cautioned against using non‐steroidal anti‐inflammatory drugs, fish oils, vitamin E and aspirin‐containing products.
Journal ArticleDOI
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Tamilla Nechiporuk,Stephen E. Kurtz,Olga Nikolova,Tingting Liu,Courtney L. Jones,Angelo D'Alessandro,Rachel Culp-Hill,Amanda d’Almeida,Sunil K. Joshi,Mara Rosenberg,Cristina E. Tognon,Alexey V. Danilov,Brian J. Druker,Bill H. Chang,Shannon K. McWeeney,Jeffrey W. Tyner +15 more
TL;DR: A genetic approach was used to identify genes whose inactivation contributes to drug resistance as a means of forming preferred drug combinations to improve AML treatment and suggest strategies to overcome resistance.
Journal ArticleDOI
Molecular Pathogenesis of Chronic Lymphocytic Leukemia
TL;DR: Molecules involved in BCR signaling pathways and cytoplasmic pro-survival players probably act in concert to confer resistance to apoptosis, and the role of the B-CLL environment, which includes nurse-like cells and T-cells, cannot be underestimated.
Journal ArticleDOI
The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-κB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells
J. Claire Godbersen,Leigh Ann Humphries,Olga V. Danilova,Peter E. Kebbekus,Jennifer R. Brown,Alan Eastman,Alexey V. Danilov +6 more
TL;DR: MLN4924 disrupts NF-κB activation and induces Bim expression in CLL cells, thereby preventing stroma-mediated resistance and enhancing the antitumor activity of the inhibitors of B-cell receptor (BCR)–associated kinases.